【摘要】 目的 :研究雷公藤多甙 (TⅡ)治疗哮喘的机制。方法 :选择中、重度哮喘发作期患者 30例 ,随机分成 3组。A组 :TⅡ 治疗组 ,B组 :泼尼松龙治疗组 ,C组 :哮喘对照组。治疗前和治疗 4周后分别用流式细胞仪 (FCM )测定外周血CD4 +、CD8+T淋巴细胞数 ,用酶联免疫吸附法 (ELISA)测血清白细胞介素 5(IL 5)的浓度。结果 :A组CD4 +T淋巴细胞由治疗前的 0 4 62± 0 0 35降至 0 4 36± 0 0 39(P <0 0 1) ,CD8+T淋巴细胞由治疗前的 0 2 0 1± 0 0 4 5升至 0 2 53± 0 0 4 3(P <0 0 1) ,血清IL 5中位浓度由 65 3ng/L降至10 9ng/L(P <0 0 1)。B组各指标治疗后变化与A组相似 ,而C组各指标治疗后均无明显改变。患者血清IL 5浓度与外周血CD4 +T淋巴细胞数成正相关 (r =0 61,P <0 0 1)。结论 :TⅡ 通过调节哮喘患者T淋巴细胞亚群的紊乱 ,抑制IL 5的生成而对哮喘炎症产生治疗作用。更多还原

【Abstract】 To investigate the therapeutic mechanism of Tripterygium polyglucoside (T Ⅱ) in treating asthma patients. Methods: Thirty asthma patients of middle or sever leoel were selected and randomly divided into three groups, Group A treated with T Ⅱ, Group B treated with prednisone and Group C, the control group. Their peripheral CD 4 +, CD 8 + T-lymphocytes were counted by flow cytometer and serum interleukin-5 (IL-5) level determined by ELISA before and after 4 weeks′ treatment. Results: In Group A, after treatment, CD 4 + T-lgmphocytes reduced from 0.462±0.035 to 0.426±0.039 (P<0 01), CD 8 + increased from 0.201±0.045 to 0.253±0.043 (P<0 01), and serum IL-5 median concentration reduced from 65.3 ng/L to 10.9 ng/L (P<0 01). Similar results was revealed in Group B, while there was insignificant change of the parameters in Group C. The serum concentration of IL-5 was positively correlated with the peripheral CD 4 + count (r=0.61, P<0 01). Conclusion: T Ⅱ is highly effective in treating asthma through regulating T-lymphocyte subset disorder and inhibiting production of IL-5.更多还原